Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash from Financing Activities (2016 - 2025)

Fate Therapeutics' Cash from Financing Activities history spans 14 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 46.01% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $5.5 million, down 94.5%, while the annual FY2025 figure was $5.5 million, 94.5% down from the prior year.
  • Cash from Financing Activities reached $1.7 million in Q4 2025 per FATE's latest filing, down from $2.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $438.0 million in Q1 2021 to a low of -$180000.0 in Q4 2023.
  • Average Cash from Financing Activities over 5 years is $33.4 million, with a median of $2.5 million recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: crashed 111.87% in 2023, then soared 46029.47% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $3.4 million in 2021, then tumbled by 55.62% to $1.5 million in 2022, then plummeted by 111.87% to -$180000.0 in 2023, then soared by 1838.89% to $3.1 million in 2024, then crashed by 46.01% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Cash from Financing Activities are $1.7 million (Q4 2025), $2.5 million (Q3 2025), and $1.3 million (Q2 2025).